Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay

marketwatch.com/story/novo-nordisk-is-no-longer-a-buy-at-ubs-which-says-compounding-is-here-to-stay-62d210a3

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said on Tuesday.

This story appeared on marketwatch.com, 2025-08-05 09:21:00.
The Entire Business World on a Single Page. Free to Use →